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Abstract
Background: In Japan, the clinical characteristics and recent serotype distribution among adult patients of invasive
pneumococcal disease (IPD) have not been fully investigated since the introduction of the pneumococcal conjugate
vaccine (PCV) in children. From November 2010, PCV7 was encouraged by an official program, funded by government,
subsequently included in the routine schedule in April 2013, and replaced with a PCV13 in November 2013.
Methods: Between April 2013 and March 2015, patients with IPD older than 15 years were evaluated based on the
enhanced national surveillance in ten prefectures of Japan. The serotype distribution of the isolates was analyzed in
these patients.
Results: The analysis included 291 patients: 107 patients (37%) were female and the median age was 70 years.
Of 281 patients with available data, 202 (72%) had underlying diseases, including 107 patients (38%) with
immunocompromised status. The case fatality proportion for all case was 20%. In subgroup analysis, the case
fatality proportion (29%) in immunocompromised patients was much higher than that (0–16%) in each age
group of nonimmunocompromised patients (15–39 years, 40–64 years, and ≥ 65 years). While the proportion
of bacteremia without any focus (27%) was higher than that (8–10%) in nonimmunocompromised patients,
the proportions of vaccine types (PCV13, 32%; PPSV23, 51%) of the causative isolates were lower than those
in each age group of nonimmunocompromised patients. Among 291 isolates, the most frequent serotypes
were 3 (17%), 19A (13%), and 22F (10%). Twelve percent of the isolates were PCV7 serotypes, 46% were
PCV13 serotypes, and 66% were PPSV23 serotypes.
Conclusions: The majority of adult patients of IPD had underlying diseases, including immunocompromised
conditions. A low proportion (12%) of PCV7-type IPD was observed in this population where PCV7 for
children had been included in the routine immunization schedule.
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Background
Streptococcus pneumoniae frequently colonizes the naso-
pharyngeal tract of children and causes noninvasive
infections, such as otitis media and nonbacteremic pneu-
monia. Furthermore, it can cause meningitis, bacteremic
pneumonia, bacteremia/septicemia, and other invasive
pneumococcal diseases (IPDs) [1, 2].
The introduction of a heptavalent pneumococcal con-
jugate vaccine (PCV7) has dramatically reduced the inci-
dence of invasive pneumococcal disease (IPD) among
vaccinated young children [3–6] and, as a result of herd
immunity, has decreased IPD among the elderly. How-
ever, non-PCV7-type IPD has increased 35 years after
PCV7 introduction among adults. This increase may
have occurred because of serotype replacement, a
phenomenon in which the prevalence of nonvaccine se-
rotypes rises while that of vaccine serotypes falls [7].
PCV7 was approved for voluntary vaccination for chil-
dren in February 2010 in Japan. From November 2010,
PCV7 vaccination was further encouraged for children
aged <5 years by an official program, the Provisional
Special Fund for the Urgent Promotion of Vaccination
by the Japanese government. PCV7 was included in the
routine schedule in April 2013, and replaced with a 13-
valent pneumococcal conjugate vaccine (PCV13) in
November 2013. Consequently, a high vaccination rate
(94.2%) was observed in children at 24 months of age in
2015 [Sakiyama H, Oishi K, unpublished data]. For
adults, a 23-valent pneumococcal polysaccharide vaccine
(PPSV23) was approved in 1988 and included in routine
immunization in October 2014 for individuals aged 65
years or older, and PCV13 was approved for adults aged
65 years or older in June 2014, on a voluntary basis.
After the introduction of PCV7, a decrease of 98% in the
incidence of IPD caused by the PCV7 serotypes was re-
ported in Japan [8]. This resulted in the 57% decline in
overall IPD, although an increase of IPD incidence
caused by PCV13 minus PCV7 serotypes and non-
PCV13 serotypes among children younger than 5 years
of age was observed [8]. However, the epidemiology of
IPD in Japan, including its serotype distribution among
adults, after the introduction of PCV for children re-
mains unknown.
In this paper, we describe the disease characteristics
and serotype distribution of pneumococcal isolates in




A national surveillance program (National Epidemiological
Surveillance of Infectious Diseases: NESID) for IPD has
been in place under the Infectious Disease Control Law of
Japan since April 2013. Physicians in all clinics and
hospitals are required to notify all cases to local public
health authorities within 7 days of diagnosis. A case of IPD
is defined as detection of S. pneumoniae by bacterial
culture, S. pneuemoniae-specific DNA by PCR in blood
and/or cerebrospinal fluid (CSF) or a positive reaction of
latex agglutination test or immunochromatography test in
CSF. Data fields collected from cases include demographic
information, syndrome, exposure history, history of
pneumococcal vaccination and evidence for diagnosis, and
were recorded in the NESID system. The Adult IPD Study
Group (http://www.nih.go.jp/niid/ja/ibi.html) conducted
enhanced surveillance of adult IPD based on the NESID in
ten of 47 prefectures in Japan, to assess the clinical charac-
teristics and serotype distribution of pneumococcal isolates
between April 2013 and March 2015. The standardized
case-reporting form for this enhanced surveillance in-
cluded sociodemographic and clinical data on age, sex,
body mass index (BMI), smoking history, alcohol abuse,
history of PPSV23 vaccination, preceding infection of influ-
enza, current underlying diseases, immunocompromised
conditions, and outcome.
We enrolled all adult IPD patients (defined as IPD pa-
tients older than 15 years of age) from the ten enhanced
surveillance prefectures (Hokkaido, Miyagi, Yamagata,
Niigata, Mie, Nara, Kochi, Fukuoka, Kagoshima, and
Okinawa prefectures) in Japan. The ten prefectures were
chosen for their relatively even distribution across the
country and willingness to participate in the study
(Additional file 1). The IPD patients older than 15 years
of age reported to NESID from the ten enhanced sur-
veillance prefectures comprised 21% (567/2752; unpub-
lished data) of the total reported IPD patients older than
15 years of age in Japan over the study period. In study
sites, a physician who diagnosed a patient as having IPD
notified the local public health department and en-
hanced surveillance personnel in the home prefecture of
the patient. The case fatality was defined as reporting of
death by the case-reporting form at the time of notifica-
tion in this study. These case-reporting forms were
collected from physicians, then sent to the Infectious
Diseases Surveillance Center (IDSC) at the National
Institute of Infectious Diseases (NIID) for analysis. One
isolate per patient was included in this analysis.
Serotyping
Isolated strains from blood and/or CSF were sent to the
prefectural and municipal public health institutes from
hospitals located in the study area, in cooperation with
local public health centers. Some pneumococcal isolates
were serotyped by multiplex serotyping PCR at the pre-
fectural public health institutes [9]. All pneumococcal
isolates, including isolates serotyped by multiplex sero-
typing PCR at the prefectural public health institutes,
were sent to the Department of Bacteriology I, NIID and
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serotyped by capsule quelling reaction with rabbit anti-
sera (Statens Serum Institute, Copenhagen, Denmark),
as described elsewhere [10].
Descriptive analysis
Data were entered, managed, and analyzed using MS Excel.
We calculated the proportions of recorded IPD patient
characteristics stratified by age and immunocompromised
status in four groups: group 1: 15–39 years, non-
immunocompromised; group 2: 40–64 years, nonimmuno-
compromised; group 3: ≥ 65 years, nonimmunocompro-
mised; and group 4: ≥ 15 years, immunocompromised.
Results
Study population and clinical features of IPD patients
Between April 2013 and March 2015, a total of 303 IPD
cases (101 cases from April 2013 to March 2014, 202
cases from April 2014 to March 2015) were registered in
the ten enhanced surveillance prefectures, among cases
reported to NESID from the ten prefectures (n = 567;
unpublished data) in study period. Among the 303 re-
ported IPD cases, bacterial culture of blood or CSF was
positive for S. pneumoniae in 301 cases at each medical
institution. In two cases, PCR test targeting lytA was
positive (blood or CSF sample was positive for each one
case) at NIID [9]. No discordant results were found in
124 isolates between the isolates serotyped by capsule
quelling reaction with rabbit antisera at NIID and those
serotyped by multiplex serotyping PCR at the prefectural
public health institutes. Among the 301 cases with posi-
tive bacterial culture, pneumococcal isolates were not
collected at NIID in six cases and the case-report form
was not obtained in four cases. We therefore analyzed
291 cases (96%) for whom both case-report data and iso-
late data were available.
The characteristics of the 291 IPD patients are sum-
marized in Table 1; 37% were female, the median age
(interquartile range, IQR) was 70 (61–81) years, and 65%
of patients were aged ≥65 years. The proportion of pa-
tients vaccinated with PPSV23 within the previous 5
years was 7%. No patients had a vaccination history of
PCV13. Comorbidity was reported in 72% of the 281 pa-
tients, and 38% had at least one immunocompromised
status, of which malignancy (20%) was the most com-
mon. Among 173 pneumonia cases, 170 cases (98%)
were diagnosed based on pulmonary infiltration in chest
radiograph and/or chest computed tomography and
three cases were diagnosed by isolation of S. pneumoniae
on sputum sample. Among 46 meningitis cases, 83%
were diagnosed by isolation of S. pneumoniae or detec-
tion of pneumococcal antigen from CSF; eight cases
were diagnosed by blood culture and the presence of
meningeal signs. The case fatality proportion for all
cases was 20% at the time of reporting. The median time
Table 1 Characteristics of IPD patients in 10 prefectures in
Japan (n = 291) from April 2013 to March 2015
Variable n/Na (%)
Female 107/291 (37)
Median age; years (IQR) 70 (61-81)
Age group
15–39 years 15/291 (5)
40–64 years 86/291 (30)
≧65 years 190 (65)
BMI
Normal or Healthy Weight (18.5 – 24.9) 139/248 (56)
Overweight (25.0 and Above) 41/248 (17)
Underweight (Below 18.5) 68/248 (27)
Smoking history 132/256 (52)
Alcohol abuse 39/257 (15)
Preceding influenza 11/192 (6)
Vaccination history of PPSV23 16/231 (7)
Comorbidities 202/281 (72)
Chronic pulmonary disease 24/281 (9)
Chronic heart disease 19/281 (7)
Chronic liver disease 19/281 (7)
Chronic kidney disease 17/281 (6)
Diabetes mellitus 34/281 (12)
Immunocompromised status 107/281 (38)
Hyposplenia/asplenia 14/271 (5)
Autoimmune disease 33/281 (12)
Corticosteroid therapy 26/281 (9)
Malignancy 56/281 (20)
Solid cancer 37/281 (13)
Hematologic cancer 17/281 (6)
Anti-cancer agent 22/281 (8)
Clinical presentation
Bacteremia without any focus 47/291 (16)
Meningitis 46/291 (16)
Bacteremic pneumonia 173/291 (59)
Othersb 25/291 (9)
Serotype
PCV13 type 135/291 (46)
PPSV23 type 191/291 (66)
Outcomec
Fatal 57/291 (20)
IQR Interquartile range, BMI Body mass index, PPSV23 23-valent pneumococcal
polysaccharide vaccine
a Number of available answers
b Others included bacteremic arthritis, bacteremic cellulitis, bacteremic
spondylitis bacteremic cholangitis, bacteremic empyema, infected aortic
aneurysm and infective endocarditis
c The case fatality was defined as reporting of death by the case-reporting
form at the time of reporting
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from patient onset to case reporting was 35 (IQR, 20–
94) days. Among fatal cases, 77% (44/57) had underlying
diseases.
Clinical features of IPD patients stratified by age and
immunocompromised status
The characteristics of the 281 IPD patients stratified by
age and immunocompromised status are shown in
Table 2. The proportion of bacteremia without any focus
(27%) was higher in Group 4 (immunocompromised
patients) than that in Group 1, 2 or 3 (each group of
nonimmunocompromised patients). The case fatality
proportion in Group 4 (29%) was much higher that (0–
16%) in Group 1, 2 or 3. The proportions of vaccine
types (PCV13, 32%; PPSV23, 51%) of the causative isolates
in Group 4 were lower than those in Group 1, 2 or 3.
Serotype distribution of pneumococcal isolates
Among the 291 isolates, the most frequent causative
serotype was 3 (49 isolates; 17%), followed by 19A (37
isolates; 13%) and 22F (30 isolates; 10%). No nontypeable
pneumococcal isolates was found. Twelve percent of the
isolates were PCV7 serotypes, 46% were PCV13 sero-
types, and 66% were PPSV23 serotypes (Fig. 1). The
PPSV23 minus PCV13 serotypes accounted for 22%.
Non-vaccine serotypes 15A (20 isolates; 7%), 23A (19
isolates; 7%), 6C (17 isolates; 6%), and 35B (12 isolates;
4%) were also frequently isolated. The proportions of
non-vaccine types of the causative organisms in Group 4
were higher that in Group 1, 2 or 3 (Additional file 2).
Among the 16 IPD patients who had received a vaccin-
ation with PPSV23 within 5 years of the onset of illness,
six (38%) had disease caused by PPSV23 serotypes, such
as 3, 14, 7F, 22F, 23F, and 33F.
Discussion
This study reports the characteristics and serotype distri-
bution of causative isolates among adult patients with
IPD. The majority of patients had underlying diseases,
including immunocompromised conditions.
The proportion of patients in our study whose IPD
was preceded by influenza (6%) was in agreement with a
previous study reported in the US [11]. As the current
proportion of vaccination with PPSV23 among the
Table 2 Characteristics of IPD patients by age and immunocompromised status (n = 281)
Group 1 n = 10 (15–39 years,
Nonimmunocompromised)
Group 2 n = 48 (40–64 years
Nonimmunocompromised)
Group 3 n = 116 (> = 65 years,
Nonimmunocompromised)
Group 4 n = 107 (> = 15 years
Immunocompromised)
Variable n/Na (%) n/Na (%) n/Na (%) n/Na (%)
Female 3/10 (30) 10/48 (21) 46/116 (40) 44/107 (41)
BMI
Normal or Healthy Weight (18.5 – 24.9) 5/7 (71) 24/42 (57) 57/95 (60) 47/97 (48)
Overweight (25.0 and Above) 0/7 (0) 11/42 (26) 12/95 (13) 17/97 (18)
Underweight (Below 18.5) 2/7 (29) 7/42 (17) 26/95 (27) 33/97 (34)
Smoking history 5/9 (56) 26/44 (59) 49/100 (49) 48/95 (51)
Alcohol abuse 2/9 (22) 13/43 (30) 13/103 (13) 11/95 (12)
Preceding influenza 0/4 (0) 2/34 (6) 8/83 (10) 1/66 (2)
Vaccination history of PPSV23 0/8 (0) 1/40 (3) 6/91 (7) 9/85 (11)
Comorbidities 1/10 (10) 25/48 (52) 69/116 (59) 107/107 (100)
Clinical presentation
Bacteremia without any focus 1/10 (10) 4/48 (8) 12/116 (10) 29/107 (27)
Meningitis 3/10 (30) 9/48 (19) 18/116 (16) 14/107 (13)
Bacteremic pneumonia 6/10 (60) 27/48 (56) 80/116 (69) 54/107 (50)
Othersb 0/10 (10) 8/48 (17) 6/116 (5) 10/107 (9)
Outcomec
Fatal 0/10 (0) 6/48 (13) 18/116 (16) 31/107 (29)
Serotype
PCV13 type 4/10 (40) 27/48 (56) 65/116 (56) 34/107 (32)
PPSV23 type 7/10 (70) 38/48 (79) 85/116 (73) 55/107 (51)
BMI Body mass index, PPSV23 23-valent pneumococcal polysaccharide vaccine
a Number of available answers
b Others included bacteremic arthritis, bacteremic cellulitis, bacteremic spondylitis bacteremic cholangitis, bacteremic empyema, infected aortic aneurysm and
infective endocarditis
c The case fatality was defined as reporting of death by the case-reporting form at the time of reporting
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elderly (older than 65 years of age) in Japan is estimated
to be approximately 33% (estimated by the reported
number of shipped doses of PPSV23 from MSD K.K.
Japan between Jan 1st 2009 and March. 31th 2015/
Japanese population older than 65 year-old (Oct. 1st
2012 national statistics [12], the proportion of vaccination
with PPSV23 (9%; 13/150) in adult IPD patients ≥ 65 years
of age found in this study was very low. This low
vaccination proportion is likely explained by the rea-
son why we calculated the vaccination proportion
based on IPD case series; however, these results indi-
cate that it is critical to encourage the unvaccinated
elderly to receive a PPSV23 vaccination via the rou-
tine immunization program.
The results of our study suggest that the introduction
of PCV7 followed by PCV13 in children may have re-
duced the coverage proportions of PCV13 and PPSV23
from 61% and 85% to 46% and 66%, respectively, com-
pared with the proportions observed in 2006–2007 [13].
Although the surveillance sites and the method of
sample collection differed between the two studies,
the factors that affect serotype distribution, such as
age and comorbidities, were found to be equivalent.
From November 2010, PCV7 was promoted by the
Japanese government for children aged < 5 years by
the Provisional Special Fund for the Urgent Promotion of
Vaccination. Thereby, all children aged < 5 years were sub-
sidized for the vaccination of PCV7. Since then, vaccin-
ation coverage of PCV7 has increased among children in
Japan. Subsequently, serotype replacement in children
after PCV7 introduction was reported from the prospect-
ive population based on surveillance from 2008 to 2013
among 10 selected prefectures in Japan [8], of which
seven prefectures were included in our study sites.
Furthermore, a recent publication reported that the
coverage proportions of PCV13 and PPSV23 had de-
creased for isolates from adult cases of IPD between
2010 and 2013, as assessed by hospital-based surveil-
lance performed in Japan [14]. Our study of adult
IPD, which was performed between April 2013 and
March 2015, demonstrated that the coverage propor-
tions of PCV13 (46%) and PPSV23 (66%) for isolates
from all IPD cases (n = 291) were >10% lower than
those detected for all IPD cases between April 2010
and March 2013. Collectively, these findings suggest
the effects of immunization with PCV7 among children
may have had indirect effects on adult IPD cases.
Serotypes 3, 19A, and 22F were the most common iso-
lates among adult patients with IPD in our study. Ac-
cording to previous data, serotype 19A was frequently
isolated from pediatric IPD cases in Japan, whereas sero-
types 3 and 22F were rarely isolated from these cases be-
tween 2011 and 2013 [8]. After the introduction of
PCV13 for children, serotype 19A (included in PCV13)
appeared to decrease among adult patients with IPD
overseas [15], and therefore we need to observe carefully
any changes in serotype 19A isolation among adult IPD
cases caused by the indirect effect of PCV13 among chil-
dren by continuing the surveillance. Furthermore, we
wonder whether the incidence of IPD caused by serotype
3 decreases after the introduction of PCV13 among chil-
dren. Although a 44% reduction of IPD incidence caused
by serotype 3 was reported in the UK among individuals
who were aged 65 years or older after the introduction
of PCV13 for children, a herd immunity effect against
serotype 3 is unclear worldwide [15, 16]. In addition, the
immunogenicity of PCV13 against serotype 3 remains
controversial in children and was reported to be lower
than that of PCV13 serotypes other than serotype 3 in
the elderly [17–20].
Fig. 1 Distribution of the serotypes of causative pneumococcal isolates (n = 291) from patients with invasive pneumococcal diseases from 10
prefectures in Japan, from April 2013 to March 2015 grouped by vaccine serotype
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The proportion of vaccine types was lower in im-
munocompromised patients than those in each age
group of nonimmunocompromised patients in our
study. This finding is consistent with those reported by
Luján et al. [21]. Those authors reported that serotypes
not included in PCV13/PPSV23 were isolated more
frequently in patients with cardiac and respiratory co-
morbidities and in certain subgroups of immunocom-
promised patients, such as HIV-infected individuals and
those with hematologic cancer. This finding suggests
that monitoring the emergence of non-vaccine serotypes
is crucial, especially in patients with specific underlying
conditions.
This study had several limitations. The proportion of
cases available for both case-report data and isolate data
was 51% (291/567) among cases reported to national
surveillance sites from the ten selected prefectures in
this study, and reporting of some variables was incom-
plete, such as preceding influenza was not available for
34% of IPD patients; therefore, it may not represent the
population of interest. The number of registered cases in
the enhanced surveillance data increased annually (101
cases from April 2013 to March 2014 vs 202 cases from
April 2014 to March 2015). Laboratory method or the
procedure of specimen collection was unchanged during
this period. The annual increase of registered cases
might be explained by the improved flow of collecting
isolates and case reporting forms from hospitals to NIID
through local public health institutes during the study
period, and heightened awareness of the IPD surveil-
lance. This explanation is supported by the finding that
the number of reported cases from the 10 selected pre-
fectures to NESID increased during the study period
(224 cases from April 2013 to March 2014 vs 343 cases
from April 2014 to March 2015). The patients whose
culture results were positive for S. pneumoniae in the
normally sterile sites other than blood or CSF were not
included because of the notification criteria of IPD in
NESID; thus our results may be an underestimation.
Conclusion
This study reported the characteristics of adult IPD and
the serotype distribution of causative pathogens in Japan
from April 2013 to March 2015. A lower proportion of
PCV7-type IPD in our study period after PCV7 intro-
duction in children compared to that in previous studies
by others before PCV7 introduction suggests there may
have been indirect effects of the infant immunization
program on adult disease. The enhancement and con-
tinuation of the nationwide surveillance of IPD in
adults are essential for evaluating IPD incidence and
serotype distribution in adults, as well as the effect of
herd immunity through the vaccination of children
with PCV13.
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Group 2 (40-64y, nonimmunocompromised) n = 48 (B), Group 3
(> = 65y, nonimmunocompromised) n = 116 (C), Group 4 (> = 15y
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